Now Enrolling: EA4181 Trial For Mantle Cell Lymphoma

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly-Diagnosed Mantle Cell Lymphoma

Mantle cell lymphoma ( MCL) is an aggressive form of lymphoma, and the optimal upfront treatment is still unknown. This phase II trial will compare three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and evaluate how well each one works in treating patients with newly diagnosed MCL.

This study is led by Nina D. Wagner-Johnston, MD (Johns Hopkins University).

Learn more about EA4181 at ecog-acrin.org.